Patents Assigned to Quest Diagnostics Investments Incorporated
  • Patent number: 11622060
    Abstract: Systems and methods are provided though which a transaction, e.g., in a multi-tier, distributed application may be initiated from a portable or hand-held device, such as a smartphone. A computer system or systems, possibly remote from the device, may approve the transaction, complete it, or both, and the remote computer system or systems may cause a document to be printed, e.g., by a printer physically proximate to the device. Aspects of the invention are illustrated by embodiments in which a drug prescription may be created electronically using a hand-held device. In such an embodiment, the prescription may be transmitted to one or more remote computer systems, such as an application server, for processing. If specified, the remote computer systems may cause a prescription to be printed, e.g., at a printer near the prescriber's location. The prescriber may sign the printed prescription and give it to a patient or pharmacy.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: April 4, 2023
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: John Koehl
  • Publication number: 20230058329
    Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
    Type: Application
    Filed: May 27, 2022
    Publication date: February 23, 2023
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Maher ALBITAR, Wanlong Ma
  • Patent number: 11579154
    Abstract: Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: February 14, 2023
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel J. Clarke, Brett Holmquist, Gloria Kwang-Ja Lee, Richard E. Reitz
  • Patent number: 11549954
    Abstract: The invention relates to the detection of non-metabolized vitamin D. In a particular aspect, the invention relates to methods for detecting underivatized non-metabolized vitamin D by mass spectrometry.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: January 10, 2023
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Brett Holmquist, Nigel Clarke
  • Patent number: 11543415
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: January 3, 2023
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E Reitz
  • Patent number: 11485967
    Abstract: Provided herein are methods and systems for cell-free DNA extraction from liquid biological samples. The methods can be employed for determination of fetal DNA fraction and non-invasive prenatal screening of fetal aneuploidies and analyses of other types of cell-free DNA.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: November 1, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Ben Anderson, Charles Strom, David Tsao, Yan Liu, Weimin Sun
  • Patent number: 11486007
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 1, 2022
    Assignees: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • Publication number: 20220326260
    Abstract: Provided are methods for determining the amount of estradiol in a sample using mass spectrometry. The methods generally involve ionizing estradiol in a sample and detecting and quantifying the amount of the ion to determine the amount of estradiol in the sample.
    Type: Application
    Filed: May 3, 2022
    Publication date: October 13, 2022
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. GOLDMAN, Nigel J. CLARKE, Richard E. REITZ
  • Publication number: 20220308021
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Application
    Filed: June 13, 2022
    Publication date: September 29, 2022
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa BOYADZHYAN, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • Patent number: 11454637
    Abstract: Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 27, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Cory Bystrom, Shijun Sheng, Nigel Clarke, Richard E. Reitz
  • Patent number: 11428682
    Abstract: Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of norendoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein determine the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: August 30, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Nigel Clarke
  • Patent number: 11421285
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 23, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Publication number: 20220214364
    Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. Goldman, Richard E. Reitz
  • Patent number: 11378435
    Abstract: An apparatus and method are provided to evaluate an amount of a biological sample in a specimen container. A fixture has a bottom surface configured to support a specimen container. A reference indicator is disposed at a predetermined height relative to the bottom surface. The reference indicator is configured to facilitate a visual comparison of the reference indicator with a height of a volume of a biological sample in the specimen container.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 5, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Christine Amendt, Sevag Bedrosian, Gordon Love, Mkrtich Daniyelyan, Miguel Torrero
  • Patent number: 11360061
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: June 14, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • Patent number: 11346845
    Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: May 31, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel Clarke, Zhaohui Chen
  • Patent number: 11333673
    Abstract: Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 17, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Karin O. Thomassian
  • Patent number: 11300559
    Abstract: Methods are described for measuring the amount of a vitamin B2 in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying vitamin B2 in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Changming Yang, Sum Chan
  • Patent number: 11280799
    Abstract: The invention relates to the detection of non-metabolized vitamin D. In a particular aspect, the invention relates to methods for detecting underivatized non-metabolized vitamin D by mass spectrometry.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: March 22, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Brett Holmquist, Nigel Clarke
  • Patent number: 11280798
    Abstract: Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: March 22, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred M. Goldman, Richard E. Reitz